Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
93.17
-0.96 (-1.03%)
Streaming Delayed Price
Updated: 12:22 PM EDT, May 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
347,774
Open
96.20
Bid (Size)
93.08 (200)
Ask (Size)
93.43 (100)
Prev. Close
94.13
Today's Range
92.84 - 96.80
52wk Range
79.52 - 124.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioNTech Announces New ADS Repurchase Program
May 07, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides
↗
May 05, 2026
Via
Chartmill
Performance
YTD
-3.6%
-3.6%
1 Month
-2.4%
-2.4%
3 Month
-15.6%
-15.6%
6 Month
-11.3%
-11.3%
1 Year
-4.2%
-4.2%
More News
Read More
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
April 21, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit
↗
March 10, 2026
Via
Chartmill
2 Healthcare Stocks to Buy and 1 to Approach With Caution
↗
April 15, 2026
Via
The Motley Fool
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
April 11, 2026
From
BioNTech SE
Via
GlobeNewswire
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
March 31, 2026
Via
Finterra
Topics
Initial Public Offering
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
March 24, 2026
From
BioNTech SE
Via
GlobeNewswire
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
March 16, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Initial Public Offering
Stocks
Why BioNTech Stock Is Getting Crushed Today
↗
March 10, 2026
Via
The Motley Fool
Gapping stocks in Tuesday's session
↗
March 10, 2026
Via
Chartmill
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
March 10, 2026
Via
MarketMinute
Stay updated with the stocks that are on the move in today's pre-market session.
↗
March 10, 2026
Via
Chartmill
Why Did BNTX Stock Tumble 17% Pre-Market Today?
↗
March 10, 2026
Via
Stocktwits
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
March 10, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
March 10, 2026
From
BioNTech SE
Via
GlobeNewswire
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
March 06, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
March 05, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
March 05, 2026
Via
Finterra
Topics
Intellectual Property
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
February 24, 2026
From
BioNTech SE
Via
GlobeNewswire
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
February 11, 2026
Via
Finterra
Topics
Artificial Intelligence
Initial Public Offering
Intellectual Property
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
January 28, 2026
From
BioNTech SE
Via
GlobeNewswire
Frequently Asked Questions
Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 93.17
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 05/11/26 12:22 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
